Tonix Pharmaceuticals is moving up from the Nasdaq Capital Market to the Nasdaq Global Market

Tonix Pharmaceuticals Holding Corp., a fully integrated biotechnology company, recently shared exciting news about its transition from the Nasdaq Capital Market to the Nasdaq Global Select Market. This upgrade was approved by Nasdaq, and trading under the existing ticker symbol “TNXP” on the Nasdaq Global Select Market started on March 3, 2026.

Moving from the Nasdaq Capital Market to the Nasdaq Global Select Market signifies Tonix’s commitment to upholding higher financial and corporate governance standards. The transition aims to enhance the company’s visibility among institutional investors, improve liquidity, and broaden market recognition. Seth Lederman, M.D., the Chief Executive Officer of Tonix Pharmaceuticals, emphasized the significance of this achievement, stating, “Uplisting to the Nasdaq Global Select Market is an important milestone for Tonix. We look forward to leveraging this enhanced platform to drive growth and create value for our shareholders.”

The Nasdaq Global Select Market is the premier tier among the three Nasdaq market tiers, offering stringent financial, liquidity, and corporate governance criteria. Companies listed on this tier are perceived to have achieved financial and operational growth, enhancing their reputation with customers, partners, and investors. This tier may also provide increased trading volumes and broader access to institutional investors.

Tonix Pharmaceuticals Holding Corp. primarily focuses on developing treatments for central nervous system (CNS) and immunology disorders with high unmet medical needs. Their flagship medication, TONMYA™, is a sublingual tablet of cyclobenzaprine HCl 2.8mg and is the first new fibromyalgia treatment in over 15 years. The company’s CNS commercial infrastructure also supports marketed products like Zembrace® SymTouch® and Tosymra® for acute migraines. Tonix is actively exploring the potential of TONMYA in treating major depressive disorder and acute stress disorder through Phase 2 clinical trials. Additionally, their CNS portfolio includes TNX-2900, a Phase 2-ready treatment for Prader-Willi syndrome, a rare disorder. The company is also advancing immunology programs with TNX-4800, a monoclonal antibody for Lyme disease prophylaxis, and TNX-1500, a CD40 ligand inhibitor for preventing kidney transplant rejection.

It’s essential to note that Tonix’s product development candidates are still under investigation, and their efficacy and safety have not yet been established or approved for any indication.

In conclusion, Tonix Pharmaceuticals’ uplisting to the Nasdaq Global Select Market marks a significant achievement for the company, reflecting its commitment to higher standards of financial and corporate governance. This move is expected to drive growth and enhance shareholder value while increasing visibility and credibility in the market. Tonix’s dedication to developing innovative treatments for CNS and immunology disorders underscores its commitment to addressing critical unmet medical needs.